A Genetically Engineered Mouse Model of Neuroblastoma Driven by Mutated ALK and MYCN
Technical Report,01 Sep 2014,31 Aug 2015
Dana-Farber Cancer Institute Boston United States
Pagination or Media Count:
During the past year, we have made significant progress towards meeting the goals of the funded grant proposal. We have identified a novel therapeutic strategy for MYCN-amplified neuroblastoma using a novel first-in-class inhibitor of cyclin dependent kinase 7 and have demonstrated selective potent activity against these tumors without general toxicity. Additionally, we have determined that in tumors expressing mutated ALK but without MYCN amplification, the combination of an ALK inhibitor and a transcriptional CDK inhibitor is synergistic. Both these strategies are ripe for clinical development and testing. Finally, our collection of tumors and sympathetic ganglia during different developmental stages will enable us to delineate the genetic and epigenetic changes that occur during tumorigenesis.